|
Market Closed -
Nasdaq
16:00:00 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 4.840 USD | -3.78% |
|
+3.86% | -4.33% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Drug Development | 13.16M | 5.09M | 140M | 3.75M | 20.6M | |||||
Total Assets | 120M | 87.81M | 128M | 90.64M | 59.03M | |||||
Interest Expense | -3.96M | -6.79M | -6.12M | -2.55M | -485K | |||||
Income Tax Expense | -3.09M | -4.7M | 138K | 151K | - | |||||
CAPEX | -1.17M | -9K | - | - | - | |||||
EBT | -35.95M | -67.51M | 67.18M | -21.14M | -8.61M | |||||
D&A | 379K | 606K | 580K | - | - | |||||
Operating Income | -60.84M | -85.76M | 72.67M | -37.12M | -16.07M | |||||
Net Income | -32.87M | -62.81M | 67.04M | -21.29M | -8.61M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Russia | - | - | - | - | - | |||||
Other Non-US | - | - | - | - | - | |||||
Total Assets | 120M | 87.81M | 128M | - | - |
- Stock Market
- Stocks
- SCYX Stock
- Financials SCYNEXIS, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
